Related Experiment Video
Updated: Feb 23, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.4K
Distal technologies and type 1 diabetes management.
Danny C Duke1, Samantha Barry2, David V Wagner1
1Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA.
The Lancet. Diabetes & Endocrinology
|September 5, 2017
Summary
Distal technologies like telehealth and mobile apps enhance type 1 diabetes management. This review explores their effectiveness, challenges, and future potential for better patient self-care.
Area of Science:
- Endocrinology and Metabolism
- Digital Health
- Health Services Research
Background:
- Type 1 diabetes necessitates intensive self-management to prevent complications.
- Technological advancements have improved diabetes self-care over the past two decades.
- While proximal technologies are well-reviewed, distal technologies remain under-explored.
Purpose of the Study:
- To review the empirical literature on the effectiveness of distal technologies for type 1 diabetes management.
- To identify current information on remote electronic systems for diabetes care.
- To discuss associated challenges and future research directions.
Main Methods:
- Systematic review of empirical literature.
- Focus on distal technologies including telehealth, mobile health apps, social platforms, and patient portals.
- Analysis of effectiveness, privacy, ethics, regulatory issues, and global adoption.
Main Results:
- Distal technologies offer potential for improved type 1 diabetes self-management.
- Evidence on the effectiveness of various distal technologies is summarized.
- Key considerations such as privacy, ethics, and global adoption are discussed.
Conclusions:
- Distal technologies represent a growing area for enhancing type 1 diabetes self-management.
- Further research is needed to address knowledge gaps and optimize global adoption.
- Addressing privacy, ethical, and regulatory concerns is crucial for successful implementation.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:22Diabetes Mellitus: Overview and Type I Subtype
5.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.6K
01:22Diabetes Mellitus: Type 2 and Gestational
5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
01:16Insulin: Dosing Regimen and Adverse Effects
903
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
903
01:27Insulin Formulations: Types and Delivery
852
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
852
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.5K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.5K